For decades, niacin (as nicotinic acid) has occupied a unique position in cardiovascular health. Long before the emergence of advanced lipid testing, niacin was being studied for its ability to support healthy lipid metabolism, lipoprotein production, and vascular function. Today, amid advances in health care and lipid biomarker research, this form of vitamin B3 stands out for one reason: it is the only nutrient that has consistently demonstrated an ability to support healthy lipoprotein(a) [Lp(a)] metabolism in published clinical research.
Understanding why niacin has this unique position requires a closer look at how it influences lipid production at the source—the liver.
Niacin Works Upstream of Cholesterol Production
Many lipid-support strategies focus on cholesterol after it has already been produced. Nicotinic acid takes a different approach by influencing several metabolic pathways involved in the production and transport of lipids.
One of niacin’s primary actions occurs in adipose tissue through activation of the GPR109A receptor. This interaction reduces hormone-sensitive lipase activity and decreases the release of free fatty acids from fat cells into circulation.
Why is this important?
The liver relies heavily on circulating free fatty acids as raw material for triglyceride production. When fewer free fatty acids reach the liver, there is less substrate available for hepatic triglyceride synthesis.
In effect, niacin helps reduce the flow of lipid building blocks entering the liver.
Supporting Healthy VLDL Production
As hepatic triglyceride production decreases, the liver produces fewer very-low-density lipoprotein (VLDL) particles.
VLDL serves as the primary transport vehicle for triglycerides leaving the liver. Over time, VLDL particles are converted into intermediate-density lipoproteins (IDL) and ultimately low-density lipoproteins (LDL).
By helping support healthy VLDL production, nicotinic acid influences multiple stages of lipid transport throughout the body.
Research also suggests niacin may inhibit diacylglycerol acyltransferase-2 (DGAT2), an enzyme involved in triglyceride synthesis within hepatocytes. This additional mechanism further contributes to its influence on hepatic lipid metabolism.
The Lipoprotein(a) Difference
Perhaps the most intriguing aspect of nicotinic acid is its relationship with lipoprotein(a).
Lp(a) has emerged as one of the most important inherited biomarkers for cardiovascular health. Unlike LDL cholesterol, which is strongly influenced by diet and lifestyle, Lp(a) levels are largely genetically determined and often remain relatively stable throughout life.
Most nutritional ingredients have little measurable impact on Lp(a).
Nicotinic acid is the exception.
Multiple clinical studies and meta-analyses have demonstrated that nicotinic acid can support healthy Lp(a) metabolism. While the exact mechanisms remain under investigation, current evidence suggests niacin may influence hepatic production and secretion of apolipoprotein(a), the unique protein component that distinguishes Lp(a) from LDL particles.
To date, nicotinic acid remains the only nutrient with published clinical evidence demonstrating a consistent ability to influence Lp(a) metabolism.
For practitioners working with patients looking for support to help maintain healthy Lp(a) metabolism, this distinction is particularly noteworthy.
Beyond Lipids: A Role in Cellular Energy
Nicotinic acid is also a precursor to nicotinamide adenine dinucleotide (NAD+), one of the body’s most important metabolic cofactors.
NAD+ participates in:
- Cellular energy production
- Mitochondrial function
- Oxidative metabolism
- Cellular repair processes
Because NAD+ levels naturally decline with age, niacin’s role extends beyond lipid metabolism into broader aspects of healthy aging and metabolic function.
The Compliance Challenge
Despite its unique benefits, niacin has historically faced one significant obstacle: patient compliance.
The most common reason patients discontinue niacin is flushing—a temporary sensation of warmth, redness, or itching that occurs when prostaglandin-mediated vasodilation increases blood flow to the skin.
Although flushing is generally harmless and often decreases with continued use, it can discourage patients from remaining compliant long enough to achieve meaningful benefits.
This is where formulation matters.
Why Extended-Release Matters
Endur-Acin® ER utilizes SmartMatrix™ extended-release technology to gradually release nicotinic acid over approximately 6–8 hours.
Rather than delivering a large amount of niacin immediately, the SmartMatrix™ system provides a controlled release profile designed to improve tolerability and support patient adherence.
Clinical studies evaluating the Endur-Acin® ER wax-matrix delivery system have consistently reported low flushing-related discontinuation rates, averaging approximately 4–5% with typical dosages in the range of 1-2 g/day. This suggests that controlled delivery can play an important role in improving the patient experience.*
The benefits of extended release include:
- Reduced intensity of flushing
- Improved patient comfort
- Simplified twice-daily dosing
- Consistent nutrient exposure over time
- Improved long-term compliance
For many practitioners, the greatest advantage of extended-release niacin is not simply pharmacokinetics—it is the ability to keep patients on protocol.
Better Compliance Leads to Better Outcomes
Nicotinic acid remains one of the most extensively researched nutritional interventions for supporting healthy lipid metabolism. Its ability to influence hepatic triglyceride production, VLDL synthesis, and lipoprotein(a) metabolism continues to distinguish it from other nutritional ingredients.
Yet even the most effective intervention is only useful if patients continue taking it. By combining nicotinic acid with SmartMatrix® extended-release technology, clinically studied Endur-Acin® ER is designed to address one of the most important challenges in clinical practice: helping patients stay compliant long enough to experience the benefits of a well-designed protocol.
In lipid management, mechanism matters. But compliance may matter even more.
References
Aronov DM, Keenan JM, Akhmedzhanov NM, Perova NV, Oganov RY, Kiseleva NY. Clinical trial of wax-matrix sustained-release niacin in a Russian population with hypercholesterolemia. Arch Fam Med. 1996;5(10):567-575. doi:10.1001/archfami.5.10.567
Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005;258(2):94-114. doi:10.1111/j.1365-2796.2005.01528.x
Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol. 2007;99(6A):22C-31C. doi:10.1016/j.amjcard.2006.11.018
Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008;101(8A):20B-26B. doi:10.1016/j.amjcard.2008.02.029
Keenan JM, Fontaine PL, Wenz JB, Myers S, Huang ZQ, Ripsin CM. Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med. 1991;151(7):1424-1432. doi:10.1001/archinte.151.7.1424
McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA. 1994;271(9):672-677.
McReynolds MR, Chellappa K, Baur JA. Age-related NAD+ decline. Exp Gerontol. 2020;134:110888. doi:10.1016/j.exger.2020.110888
Sahebkar A, Reiner Ž, Simental-Mendía LE, Ferretti G, Cicero AF. Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. Metabolism. 2016;65(11):1664-1678. doi:10.1016/j.metabol.2016.08.007
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
SmartMatrix is a trademark of Innovite, Inc.
